{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:10Z","timestamp":1791917830402,"version":"4.3.4"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40265-025-02198-6","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:05:55Z","timestamp":1750475155000},"page":"1013-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"85","author":[{"given":"Naya","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2198_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10461-3","author":"C Fonseca","year":"2024","unstructured":"Fonseca C, Garagarza C, Silva G, Caires G, Marques I, Lopes JA, et al. Hyperkalemia management: a multidisciplinary expert panel\u2019s perspective on the role of new potassium binders. Heart Fail Rev. 2024. https:\/\/doi.org\/10.1007\/s10741-024-10461-3.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"2198_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","volume":"26","author":"J Silva-Cardoso","year":"2021","unstructured":"Silva-Cardoso J, Brito D, Frazao JM, Ferreira A, Bettencourt P, Branco P, et al. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev. 2021;26(4):891\u20136. https:\/\/doi.org\/10.1007\/s10741-020-10069-3.","journal-title":"Heart Fail Rev"},{"key":"2198_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835","volume":"172","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021;172: 105835. https:\/\/doi.org\/10.1016\/j.phrs.2021.105835.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2198_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2198_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213192","volume":"14","author":"M Jun","year":"2019","unstructured":"Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS ONE. 2019;14(3): e0213192. https:\/\/doi.org\/10.1371\/journal.pone.0213192.","journal-title":"PLoS ONE"},{"issue":"7","key":"2198_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2215\/CJN.02130221","volume":"16","author":"YJ Hwang","year":"2021","unstructured":"Hwang YJ, Lyu B, Chang AR, Inker LA, Grams ME, Shin JI. Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level. Clin J Am Soc Nephrol. 2021;16(7):1094\u20136. https:\/\/doi.org\/10.2215\/CJN.02130221.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"2198_CR7","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23(10):1698\u2013707. https:\/\/doi.org\/10.1002\/ejhf.2287.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2198_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/00015385.2020.1748346","volume":"76","author":"P Martens","year":"2021","unstructured":"Martens P, Kooij J, Maessen L, Dauw J, Dupont M, Mullens W. The importance of developing hyperkalaemia in heart failure during long-term follow-up. Acta Cardiol. 2021;76(6):589\u201397. https:\/\/doi.org\/10.1080\/00015385.2020.1748346.","journal-title":"Acta Cardiol"},{"issue":"2","key":"2198_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-related discontinuation of renin\u2013angiotensin\u2013aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80(2):164-73e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2198_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.amjcard.2013.06.039","volume":"112","author":"KK Lee","year":"2013","unstructured":"Lee KK, Shilane D, Hlatky MA, Yang J, Steimle AE, Go AS. Effectiveness and safety of spironolactone for systolic heart failure. Am J Cardiol. 2013;112(9):1427\u201332. https:\/\/doi.org\/10.1016\/j.amjcard.2013.06.039.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2198_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51\u20138. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000792.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2198_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","volume":"9","author":"KS Jering","year":"2021","unstructured":"Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021;9(1):13\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.014.","journal-title":"JACC Heart Fail."},{"issue":"20","key":"2198_CR13","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","volume":"60","author":"O Vardeny","year":"2012","unstructured":"Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60(20):2082\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.048.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2198_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.amjcard.2011.10.027","volume":"109","author":"S Muzzarelli","year":"2012","unstructured":"Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, et al. Frequency and predictors of hyperkalemia in patients >\/=60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol. 2012;109(5):693\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2011.10.027.","journal-title":"Am J Cardiol"},{"issue":"12","key":"2198_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurjhf\/hfs145","volume":"14","author":"MS Kiernan","year":"2012","unstructured":"Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail. 2012;14(12):1401\u20139. https:\/\/doi.org\/10.1093\/eurjhf\/hfs145.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2198_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573\u20139. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001104.","journal-title":"Circ Heart Fail"},{"key":"2198_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101751","volume":"55","author":"A Yang","year":"2023","unstructured":"Yang A, Shi M, Lau ESH, Wu H, Zhang X, Fan B, et al. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study. EClinicalMedicine. 2023;55: 101751. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101751.","journal-title":"EClinicalMedicine."},{"issue":"20","key":"2198_CR18","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa1303154.","journal-title":"N Engl J Med"},{"key":"2198_CR19","doi-asserted-by":"crossref","unstructured":"Kim H, Ko A. #619 Serum aldosterone to potassium ratio and hyperkalemia risk in patients with chronic kidney disease. 61st ERA Congress. 2024.","DOI":"10.1093\/ndt\/gfae069.1383"},{"issue":"12","key":"2198_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/phar.2633","volume":"41","author":"J An","year":"2021","unstructured":"An J, Niu F, Sim JJ. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI\/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021;41(12):998\u20131008. https:\/\/doi.org\/10.1002\/phar.2633.","journal-title":"Pharmacotherapy"},{"key":"2198_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020699","author":"A Di Lenarda","year":"2023","unstructured":"Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT study). J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12020699.","journal-title":"J Clin Med"},{"key":"2198_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.791446","volume":"9","author":"SJ Na","year":"2022","unstructured":"Na SJ, Youn JC, Lee HS, Jeon S, Lee HY, Cho HJ, et al. The prescription characteristics, efficacy and safety of spironolactone in real-world patients with acute heart failure syndrome: a prospective nationwide cohort study. Front Cardiovasc Med. 2022;9: 791446. https:\/\/doi.org\/10.3389\/fcvm.2022.791446.","journal-title":"Front Cardiovasc Med."},{"issue":"5","key":"2198_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00059-017-4671-1","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Sacubitril\/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study. Herz. 2019;44(5):425\u201332. https:\/\/doi.org\/10.1007\/s00059-017-4671-1.","journal-title":"Herz"},{"issue":"1","key":"2198_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/20009666.2019.1708638","volume":"10","author":"K Peppin","year":"2020","unstructured":"Peppin K, Tellor K, Armbruster A, Schwarze M. Evaluating the safety and tolerability of inpatient sacubitrilvalsartan initiation in a community hospital. J Community Hosp Intern Med Per. 2020;10(1):38\u201344. https:\/\/doi.org\/10.1080\/20009666.2019.1708638.","journal-title":"J Community Hosp Intern Med Per."},{"issue":"3","key":"2198_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000505286","volume":"10","author":"F Lisi","year":"2020","unstructured":"Lisi F, Parisi G, Gioia MI, Amato L, Bellino MC, Grande D, et al. Mineralcorticoid receptor antagonist withdrawal for hyperkalemia and mortality in patients with heart failure. Cardiorenal Med. 2020;10(3):145\u201353. https:\/\/doi.org\/10.1159\/000505286.","journal-title":"Cardiorenal Med."},{"issue":"12","key":"2198_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.26599\/1671-5411.2023.12.005","volume":"20","author":"AH Wu","year":"2023","unstructured":"Wu AH, Lin ZW, Yang ZH, Zhang H, Hu JY, Wang Y, et al. Efficacy and safety of sacubitril\/valsartan after six months in patients with heart failure with reduced ejection fraction and asymptomatic hypotension. J Geriatr Cardiol. 2023;20(12):855\u201366. https:\/\/doi.org\/10.26599\/1671-5411.2023.12.005.","journal-title":"J Geriatr Cardiol"},{"issue":"10","key":"2198_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jcpt.13699","volume":"47","author":"C Zuo","year":"2022","unstructured":"Zuo C, Li X, Fan L, Li J, Tian D, Chen C, et al. Effectiveness and safety of sacubitril\/valsartan for patients with hypertension and heart failure in the real-world setting: a retrospective study in China. J Clin Pharm Ther. 2022;47(10):1539\u201347. https:\/\/doi.org\/10.1111\/jcpt.13699.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"2198_CR28","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ehf2.14367","volume":"10","author":"C Wang","year":"2023","unstructured":"Wang C, Lin Z, Miao D, Zhang H, Fu K, Zhang X, et al. Dose titration of sacubitril\/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail. 2023;10(3):1961\u201371. https:\/\/doi.org\/10.1002\/ehf2.14367.","journal-title":"ESC Heart Fail."},{"issue":"3","key":"2198_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cardfail.2022.10.432","volume":"29","author":"G Gjyriqi","year":"2023","unstructured":"Gjyriqi G, York M, Abuazzam F, Herzog CA, Bangalore S, Lo KB, et al. Angiotensin receptor neprilysin inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function: an analysis of the veterans administrative health system. J Card Fail. 2023;29(3):258\u201368. https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.432.","journal-title":"J Card Fail"},{"issue":"3","key":"2198_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000512418","volume":"146","author":"Y He","year":"2021","unstructured":"He Y, Lu X, Zheng Y, Song M, Shen B, Nienaber CA, et al. Efficacy and safety of sacubitril\/valsartan therapy for acute decompensated heart failure with reduced ejection fraction during the vulnerable phase: a multicenter, assessor-blinded, prospective, observational, cohort study. Cardiology. 2021;146(3):335\u201344. https:\/\/doi.org\/10.1159\/000512418.","journal-title":"Cardiology"},{"issue":"1","key":"2198_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ehf2.13164","volume":"8","author":"JB Muhlestein","year":"2021","unstructured":"Muhlestein JB, Kammerer J, Bair TL, Knowlton KU, Le VT, Anderson JL, et al. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. ESC Heart Fail. 2021;8(1):691\u20136. https:\/\/doi.org\/10.1002\/ehf2.13164.","journal-title":"ESC Heart Fail."},{"issue":"11","key":"2198_CR32","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/ejhf.2024","volume":"22","author":"M Volterrani","year":"2020","unstructured":"Volterrani M, Perrone V, Sangiorgi D, Giacomini E, Iellamo F, Degli Esposti L, et al. Effects of hyperkalaemia and non-adherence to renin\u2013angiotensin\u2013aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study. Eur J Heart Fail. 2020;22(11):2049\u201355. https:\/\/doi.org\/10.1002\/ejhf.2024.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2198_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.acvd.2020.05.017","volume":"113","author":"C Berger","year":"2020","unstructured":"Berger C, Prieur C, Bochaton T, Berthiller J, Luyt CE, Bonnefoy-Cudraz E. Patients with acute heart failure treated with the CARRESS-HF diuretic protocol in association with canrenoate potassium: Tolerance of high doses of canrenoate potassium. Arch Cardiovasc Dis. 2020;113(11):679\u201389. https:\/\/doi.org\/10.1016\/j.acvd.2020.05.017.","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"2198_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/jicc.Jicc_53_20","volume":"10","author":"P Goel","year":"2020","unstructured":"Goel P, Layek M, Sahu A, Yadav M, Khanna R, Garg N, et al. Angiotensin receptor neprilysin inhibitor in heart failure with reduced ejection fraction: real-world experience from a safety perspective. J Indian Coll Cardiol. 2020;10(4):168. https:\/\/doi.org\/10.4103\/jicc.Jicc_53_20.","journal-title":"J Indian Coll Cardiol"},{"issue":"8","key":"2198_CR35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al. Unravelling the interplay between hyperkalaemia, renin\u2013angiotensin\u2013aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22(8):1378\u201389. https:\/\/doi.org\/10.1002\/ejhf.1793.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2198_CR36","doi-asserted-by":"publisher","first-page":"16335","DOI":"10.1038\/s41598-021-95787-w","volume":"11","author":"H Kim","year":"2021","unstructured":"Kim H, Oh J, Lee S, Ha J, Yoon M, Chun KH, et al. Clinical evidence of initiating a very low dose of sacubitril\/valsartan: a prospective observational analysis. Sci Rep. 2021;11(1):16335. https:\/\/doi.org\/10.1038\/s41598-021-95787-w.","journal-title":"Sci Rep"},{"issue":"6","key":"2198_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.5830\/CVJA-2018-039","volume":"29","author":"E Laflamme","year":"2018","unstructured":"Laflamme E, Vachon A, Gilbert S, Boisvert J, Leclerc V, Bernier M, et al. Usefulness of a titration algorithm for de novo users of sacubitril\/valsartan in a tertiary centre heart failure clinic. Cardiovasc J Afr. 2018;29(6):352\u20136. https:\/\/doi.org\/10.5830\/CVJA-2018-039.","journal-title":"Cardiovasc J Afr"},{"issue":"8","key":"2198_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326. https:\/\/doi.org\/10.1002\/ejhf.1199.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2198_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jjcc.2023.11.005","volume":"84","author":"S Matsumoto","year":"2024","unstructured":"Matsumoto S, McMurray JJV, Nasu T, Ishii S, Kagiyama N, Kida K, et al. Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry. J Cardiol. 2024;84(2):133\u201340. https:\/\/doi.org\/10.1016\/j.jjcc.2023.11.005.","journal-title":"J Cardiol"},{"issue":"4","key":"2198_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ejim.2011.04.008","volume":"22","author":"S Goland","year":"2011","unstructured":"Goland S, Naugolny V, Korbut Z, Rozen I, Caspi A, Malnick S. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. Eur J Intern Med. 2011;22(4):424\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2011.04.008.","journal-title":"Eur J Intern Med"},{"key":"2198_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101149","volume":"41","author":"DY Chen","year":"2021","unstructured":"Chen DY, Chen CC, Tseng CN, Chen SW, Chang SH, Huang WK, et al. Clinical outcomes of Sacubitril\/Valsartan in patients with acute heart failure: a multi-institution study. EClinicalMedicine. 2021;41: 101149. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101149.","journal-title":"EClinicalMedicine."},{"key":"2198_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2023.01.002","volume":"258","author":"M Johnson","year":"2023","unstructured":"Johnson M, Morrison FJ, McMahon G, Su M, Turchin A. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin\u2013angiotensin\u2013aldosterone system inhibitor. Am Heart J. 2023;258:49\u201359. https:\/\/doi.org\/10.1016\/j.ahj.2023.01.002.","journal-title":"Am Heart J"},{"issue":"5","key":"2198_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40256-018-0290-3","volume":"18","author":"CJ Kapelios","year":"2018","unstructured":"Kapelios CJ, Bonou M, Vogiatzi P, Tzanis G, Mantzouratou P, Lund LH, et al. Association between high-dose spironolactone and decongestion in patients with acute heart failure: an observational retrospective study. Am J Cardiovasc Drugs. 2018;18(5):415\u201322. https:\/\/doi.org\/10.1007\/s40256-018-0290-3.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"2198_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/ehf2.12635","volume":"7","author":"JM Duran","year":"2020","unstructured":"Duran JM, Gad S, Brann A, Greenberg B. Mineralocorticoid receptor antagonist use following heart failure hospitalization. ESC Heart Fail. 2020;7(2):482\u201392. https:\/\/doi.org\/10.1002\/ehf2.12635.","journal-title":"ESC Heart Fail."},{"issue":"6","key":"2198_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/clc.23576","volume":"44","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Voors AA, Ouwerkerk W, Duarte K, Girerd N, Rossignol P, et al. Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Clin Cardiol. 2021;44(6):780\u20138. https:\/\/doi.org\/10.1002\/clc.23576.","journal-title":"Clin Cardiol"},{"issue":"11","key":"2198_CR46","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1085\u201395. https:\/\/doi.org\/10.1001\/jama.2019.12821.","journal-title":"JAMA"},{"issue":"5","key":"2198_CR47","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ejhf.1079","volume":"20","author":"JC Beusekamp","year":"2018","unstructured":"Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, et al. Potassium and the use of renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail. 2018;20(5):923\u201330. https:\/\/doi.org\/10.1002\/ejhf.1079.","journal-title":"Eur J Heart Fail"},{"key":"2198_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004675","author":"LG Gilstrap","year":"2017","unstructured":"Gilstrap LG, Fonarow GC, Desai AS, Liang L, Matsouaka R, DeVore AD, et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004675.","journal-title":"J Am Heart Assoc"},{"key":"2198_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-11-4","volume":"11","author":"J Lachaine","year":"2011","unstructured":"Lachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol. 2011;11:4. https:\/\/doi.org\/10.1186\/1472-6904-11-4.","journal-title":"BMC Clin Pharmacol"},{"issue":"4-a Suppl","key":"2198_CR50","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2017.23.4-a.s2a","volume":"23","author":"M Polson","year":"2017","unstructured":"Polson M, Lord T, Kangethe A, Speicher L, Farnum C, Brenner M, et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care S. 2017;23(4-a Suppl):S2\u20139. https:\/\/doi.org\/10.18553\/jmcp.2017.23.4-a.s2a.","journal-title":"J Manag Care S"},{"issue":"5","key":"2198_CR51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","volume":"80","author":"N Sato","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease. Circ J. 2016;80(5):1113\u201322. https:\/\/doi.org\/10.1253\/circj.CJ-16-0122.","journal-title":"Circ J"},{"issue":"1","key":"2198_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12872-023-03070-9","volume":"23","author":"MN Khan","year":"2023","unstructured":"Khan MN, Soomro NA, Naseeb K, Bhatti UH, Rauf R, Balouch IJ, et al. Safety and tolerability of sacubitril\/valsartan in heart failure patient with reduced ejection fraction. BMC Cardiovasc Disord. 2023;23(1):133. https:\/\/doi.org\/10.1186\/s12872-023-03070-9.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2198_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;82(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2198_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","volume":"347","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Nodari S, Caretta G, D\u2019Aloia A, Pezzali N, Faden G, et al. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci. 2014;347(4):271\u20136. https:\/\/doi.org\/10.1097\/MAJ.0b013e31829dd6b1.","journal-title":"Am J Med Sci"},{"issue":"2","key":"2198_CR55","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","volume":"8","author":"M Asakura","year":"2022","unstructured":"Asakura M, Ito S, Yamada T, Saito Y, Kimura K, Yamashina A, et al. Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(2):108\u201317. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa132.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"6","key":"2198_CR56","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1812851.","journal-title":"N Engl J Med"},{"issue":"16","key":"2198_CR57","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJ McMurray","year":"2016","unstructured":"McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374(16):1521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1514859.","journal-title":"N Engl J Med"},{"issue":"11","key":"2198_CR58","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"15","key":"2198_CR59","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"6","key":"2198_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ihj.2020.09.016","volume":"72","author":"AR Jain","year":"2020","unstructured":"Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S. Efficacy and safety of sacubitril\/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study. Indian Heart J. 2020;72(6):535\u201340. https:\/\/doi.org\/10.1016\/j.ihj.2020.09.016.","journal-title":"Indian Heart J"},{"issue":"1","key":"2198_CR61","doi-asserted-by":"publisher","first-page":"12517","DOI":"10.1038\/s41598-023-39779-y","volume":"13","author":"S Ito","year":"2023","unstructured":"Ito S, Takahama H, Asakura M, Abe Y, Ajioka M, Anzai T, et al. Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial. Sci Rep. 2023;13(1):12517. https:\/\/doi.org\/10.1038\/s41598-023-39779-y.","journal-title":"Sci Rep"},{"issue":"2","key":"2198_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/00015385.2018.1455947","volume":"74","author":"FH Verbrugge","year":"2019","unstructured":"Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74(2):100\u20137. https:\/\/doi.org\/10.1080\/00015385.2018.1455947.","journal-title":"Acta Cardiol"},{"issue":"1","key":"2198_CR63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/ejhf.896","volume":"20","author":"SL Kristensen","year":"2018","unstructured":"Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q, et al. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail. 2018;20(1):136\u201347. https:\/\/doi.org\/10.1002\/ejhf.896.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2198_CR64","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cardfail.2023.08.021","volume":"30","author":"E Straburzynska-Migaj","year":"2024","unstructured":"Straburzynska-Migaj E, Senni M, Wachter R, Fonseca C, Witte KK, Mueller C, et al. Early initiation of sacubitril\/valsartan in patients with acute heart failure and renal dysfunction: an analysis of the TRANSITION study. J Card Fail. 2024;30(3):425\u201335. https:\/\/doi.org\/10.1016\/j.cardfail.2023.08.021.","journal-title":"J Card Fail"},{"issue":"8","key":"2198_CR65","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","volume":"20","author":"KM Kurrelmeyer","year":"2014","unstructured":"Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail. 2014;20(8):560\u20138. https:\/\/doi.org\/10.1016\/j.cardfail.2014.05.010.","journal-title":"J Card Fail"},{"issue":"17","key":"2198_CR66","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2013.04.086.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2198_CR67","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/eurjhf\/hfr034","volume":"13","author":"B Pitt","year":"2011","unstructured":"Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail. 2011;13(7):755\u201364. https:\/\/doi.org\/10.1093\/eurjhf\/hfr034.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2198_CR68","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ejhf.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193\u2013202. https:\/\/doi.org\/10.1002\/ejhf.548.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2198_CR69","first-page":"15689","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Hou D, Ma G, Liang Y, Wang H, Wang X, et al. Effects of long-term low-dose spironolactone treatment in patients with New York Heart Association functional class II heart failure: a 10-year prospective study. Int J Clin Exp Med. 2016;9(8):15689\u201398.","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"2198_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","volume":"7","author":"DL Mann","year":"2022","unstructured":"Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, et al. Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol. 2022;7(1):17\u201325. https:\/\/doi.org\/10.1001\/jamacardio.2021.4567.","journal-title":"JAMA Cardiol."},{"issue":"1","key":"2198_CR71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017;2(1):79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733.","journal-title":"JAMA Cardiol."},{"issue":"19","key":"2198_CR72","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","volume":"326","author":"B Pieske","year":"2021","unstructured":"Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al. Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919\u201329. https:\/\/doi.org\/10.1001\/jama.2021.18463.","journal-title":"JAMA"},{"issue":"11","key":"2198_CR73","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077\u201384. https:\/\/doi.org\/10.1001\/jama.2019.12843.","journal-title":"JAMA"},{"issue":"4","key":"2198_CR74","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L, Kristensen SL, Bengtsson O, Bohm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9(4):254\u201364. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.009.","journal-title":"JACC Heart Fail."},{"issue":"12","key":"2198_CR75","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","volume":"79","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D, et al. Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2022;79(12):1129\u201337. https:\/\/doi.org\/10.1016\/j.jacc.2022.01.029.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2198_CR76","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced. J Am Coll Cardiol. 2021;77(11):1397\u2013407. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.044.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2198_CR77","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/ejhf.2982","volume":"25","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, et al. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE. Eur J Heart Fail. 2023;25(10):1797\u2013805. https:\/\/doi.org\/10.1002\/ejhf.2982.","journal-title":"Eur J Heart Fail"},{"issue":"27","key":"2198_CR78","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132.","journal-title":"Eur Heart J"},{"issue":"1","key":"2198_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray J, Krum H, Veldhuisen DV, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"issue":"5","key":"2198_CR80","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","volume":"6","author":"O Vardeny","year":"2013","unstructured":"Vardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail. 2013;6(5):970\u20136. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000530.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2198_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","volume":"167","author":"CB Bowling","year":"2013","unstructured":"Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol. 2013;167(1):151\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.056.","journal-title":"Int J Cardiol"},{"issue":"8","key":"2198_CR82","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano M, Puchades MJ, Garofalo C, Jongs N, D\u2019Marco L, Andreucci M, et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33(8):1569\u201380. https:\/\/doi.org\/10.1681\/ASN.2022020207.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2198_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16(2):293\u2013302. https:\/\/doi.org\/10.1093\/ckj\/sfac234.","journal-title":"Clin Kidney J"},{"key":"2198_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632978","volume":"12","author":"X Qu","year":"2021","unstructured":"Qu X, Yao H, Chen C, Kong S, Sun L, Du L, et al. Spironolactone improves the all-cause mortality and re-hospitalization rates in acute myocardial infarction with chronic kidney disease patients. Front Pharmacol. 2021;12: 632978. https:\/\/doi.org\/10.3389\/fphar.2021.632978.","journal-title":"Front Pharmacol"},{"key":"2198_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.824095","volume":"9","author":"E Riccio","year":"2022","unstructured":"Riccio E, Capuano I, Buonanno P, Andreucci M, Provenzano M, Amicone M, et al. RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med. 2022;9: 824095. https:\/\/doi.org\/10.3389\/fcvm.2022.824095.","journal-title":"Front Cardiovasc Med."},{"issue":"12","key":"2198_CR86","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1681\/ASN.2018040443","volume":"29","author":"V Saglimbene","year":"2018","unstructured":"Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, et al. The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): a randomized, controlled trial. J Am Soc Nephrol. 2018;29(12):2890\u20139. https:\/\/doi.org\/10.1681\/ASN.2018040443.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2198_CR87","first-page":"75","volume":"22","author":"R Abolghasmi","year":"2011","unstructured":"Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl. 2011;22(1):75\u20138.","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"2198_CR88","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1756-0500-6-306","volume":"6","author":"E Espinel","year":"2013","unstructured":"Espinel E, Joven J, Gil I, Sune P, Renedo B, Fort J, et al. Risk of hyperkalemia in patients with moderate chronic kidney disease angiotensin receptor blockers: a randomized study. BMC Res Notes. 2013;6:306. https:\/\/doi.org\/10.1186\/1756-0500-6-306.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2198_CR89","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia Risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225\u201337. https:\/\/doi.org\/10.1681\/ASN.2021070942.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2198_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184402","volume":"12","author":"Y Saito","year":"2017","unstructured":"Saito Y, Yamamoto H, Nakajima H, Takahashi O, Komatsu Y. Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors. PLoS ONE. 2017;12(9): e0184402. https:\/\/doi.org\/10.1371\/journal.pone.0184402.","journal-title":"PLoS ONE"},{"issue":"5","key":"2198_CR91","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","volume":"18","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al. Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes a FIDELITY subgroup analysis. Clin J Am Soc Nephrol. 2023;18(5):602\u201312. https:\/\/doi.org\/10.2215\/CJN.0000000000000149.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2198_CR92","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.008.","journal-title":"Kidney Int Rep."},{"issue":"1","key":"2198_CR93","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0043-106440","volume":"126","author":"FM Rasche","year":"2018","unstructured":"Rasche FM, Joel C, Ebert T, Frese T, Barinka F, Busch V, et al. Dual RAAS blockade with aliskiren in patients with severely impaired chronic kidney disease. Exp Clin Endocrinol Diabetes. 2018;126(1):39\u201352. https:\/\/doi.org\/10.1055\/s-0043-106440.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"12","key":"2198_CR94","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1038\/s41440-022-01028-6","volume":"45","author":"TH Yoo","year":"2022","unstructured":"Yoo TH, Hong SJ, Kim S, Shin S, Kim DK, Lee JP, et al. The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. Hypertens Res. 2022;45(12):2008\u201317. https:\/\/doi.org\/10.1038\/s41440-022-01028-6.","journal-title":"Hypertens Res"},{"issue":"5","key":"2198_CR95","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41371-021-00625-1","volume":"36","author":"JR Salik","year":"2022","unstructured":"Salik JR, Golas SB, McCoy TH. A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers. J Hum Hypertens. 2022;36(5):485\u20137. https:\/\/doi.org\/10.1038\/s41371-021-00625-1.","journal-title":"J Hum Hypertens"},{"issue":"8","key":"2198_CR96","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","volume":"26","author":"R Pisoni","year":"2012","unstructured":"Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell\u2019Italia LJ, Cofield SS, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26(8):502\u20136. https:\/\/doi.org\/10.1038\/jhh.2011.60.","journal-title":"J Hum Hypertens"},{"issue":"15","key":"2198_CR97","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge P, Staplin N, Herrington W, Storey B, Bethel A, et al. Effects of sacubitrilvalsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138(15):1505\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034818.","journal-title":"Circulation"},{"issue":"3","key":"2198_CR98","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/hr.2012.183","volume":"36","author":"T Yasuda","year":"2013","unstructured":"Yasuda T, Endoh M, Suzuki D, Yoshimura A, Ideura T, Tamura K, et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens Res. 2013;36(3):240\u20136. https:\/\/doi.org\/10.1038\/hr.2012.183.","journal-title":"Hypertens Res"},{"issue":"2","key":"2198_CR99","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40620-021-01070-6","volume":"35","author":"A Santoro","year":"2022","unstructured":"Santoro A, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Degli EL. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. J Nephrol. 2022;35(2):463\u201372. https:\/\/doi.org\/10.1007\/s40620-021-01070-6.","journal-title":"J Nephrol"},{"key":"2198_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2017.05.008","volume":"191","author":"MK Hayer","year":"2017","unstructured":"Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, et al. A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: rationale and design of the SPIRO-CKD trial. Am Heart J. 2017;191:37\u201346. https:\/\/doi.org\/10.1016\/j.ahj.2017.05.008.","journal-title":"Am Heart J"},{"issue":"2","key":"2198_CR101","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","volume":"96","author":"GJ Mayer","year":"2019","unstructured":"Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, et al. Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96(2):489\u2013504. https:\/\/doi.org\/10.1016\/j.kint.2019.02.033.","journal-title":"Kidney Int"},{"issue":"7","key":"2198_CR102","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jdi.13778","volume":"13","author":"K Shikata","year":"2022","unstructured":"Shikata K, Ito S, Kashihara N, Nangaku M, Wada T, Okuda Y, et al. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies. J Diabetes Investig. 2022;13(7):1190\u2013202. https:\/\/doi.org\/10.1111\/jdi.13778.","journal-title":"J Diabetes Investig."},{"issue":"23","key":"2198_CR103","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"2198_CR104","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"9","key":"2198_CR105","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394. https:\/\/doi.org\/10.1001\/jama.2015.10081.","journal-title":"JAMA"},{"issue":"6","key":"2198_CR106","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000508670","volume":"10","author":"M El Mokadem","year":"2020","unstructured":"El Mokadem M, Abd El Hady Y, Aziz A. A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy. Cardiorenal Med. 2020;10(6):392\u2013401. https:\/\/doi.org\/10.1159\/000508670.","journal-title":"Cardiorenal Med."},{"issue":"3","key":"2198_CR107","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4103\/1319-2442.182385","volume":"27","author":"B Albayrak","year":"2016","unstructured":"Albayrak B, Cankaya E, Cetinkaya R, Cerrah S, Bilen Y. The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy. Saudi J Kidney Dis Transpl. 2016;27(3):512\u20138. https:\/\/doi.org\/10.4103\/1319-2442.182385.","journal-title":"Saudi J Kidney Dis Transpl."},{"issue":"11","key":"2198_CR108","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/ndt\/gft281","volume":"28","author":"A Esteghamati","year":"2013","unstructured":"Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transplant. 2013;28(11):2823\u201333. https:\/\/doi.org\/10.1093\/ndt\/gft281.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2198_CR109","first-page":"648","volume":"4","author":"A Ziaee","year":"2013","unstructured":"Ziaee A, Vaezi AA, Oveisi S, Javadi A, Hashemipour S, Kazemifar A. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian J Intern Med. 2013;4(2):648\u201353.","journal-title":"Caspian J Intern Med"},{"issue":"4","key":"2198_CR110","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/1470320313510584","volume":"15","author":"KT Woo","year":"2014","unstructured":"Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Fook-Chong S, et al. Aliskiren and losartan trial in non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014;15(4):515\u201322. https:\/\/doi.org\/10.1177\/1470320313510584.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2198_CR111","doi-asserted-by":"publisher","first-page":"1084442","DOI":"10.3389\/fphar.2023.1084442","volume":"14","author":"JF Li","year":"2023","unstructured":"Li JF, Qu X, Gao Z, Chen CX, Zhang FY, Cheng L, et al. Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease\u2013\u2013\u2013balance of efficacy and risk. Front Pharmacol. 2023;14:1084442. https:\/\/doi.org\/10.3389\/fphar.2023.1084442.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2198_CR112","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ejhf.2740","volume":"25","author":"DS Lin","year":"2023","unstructured":"Lin DS, Lin FJ, Lin YS, Lee JK, Lin YH. The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure. Eur J Heart Fail. 2023;25(1):98\u2013107. https:\/\/doi.org\/10.1002\/ejhf.2740.","journal-title":"Eur J Heart Fail"},{"key":"2198_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.794707","volume":"9","author":"FC Hsiao","year":"2022","unstructured":"Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med. 2022;9: 794707. https:\/\/doi.org\/10.3389\/fcvm.2022.794707.","journal-title":"Front Cardiovasc Med."},{"key":"2198_CR114","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ahj.2016.03.024","volume":"178","author":"H Frohlich","year":"2016","unstructured":"Frohlich H, Nelges C, Tager T, Schwenger V, Cebola R, Schnorbach J, et al. Long-term changes of renal function in relation to ace inhibitor\/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J. 2016;178:28\u201336. https:\/\/doi.org\/10.1016\/j.ahj.2016.03.024.","journal-title":"Am Heart J"},{"issue":"7","key":"2198_CR115","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00228-020-03069-7","volume":"77","author":"AR Buckallew","year":"2021","unstructured":"Buckallew AR, Tellor KB, Watson R, Miller W, Mbachu G, Whitlock C, et al. Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. Eur J Clin Pharmacol. 2021;77(7):955\u201360. https:\/\/doi.org\/10.1007\/s00228-020-03069-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"31","key":"2198_CR116","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/eht187.","journal-title":"Eur Heart J"},{"key":"2198_CR117","doi-asserted-by":"publisher","first-page":"5935149","DOI":"10.1155\/2021\/5935149","volume":"2021","author":"HR Jun","year":"2021","unstructured":"Jun HR, Kim H, Lee SH, Cho JH, Lee H, Yim HW, et al. Onset of hyperkalemia following the administration of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Cardiovasc Ther. 2021;2021:5935149. https:\/\/doi.org\/10.1155\/2021\/5935149.","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"2198_CR118","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","volume":"33","author":"RW Thomsen","year":"2018","unstructured":"Thomsen RW, Nicolaisen SK, Hasvold P, Sanchez RG, Pedersen L, Adelborg K, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Nephrol Dial Transplant. 2018;33(9):1610\u201320. https:\/\/doi.org\/10.1093\/ndt\/gfx312.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2198_CR119","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.mayocp.2020.03.035","volume":"95","author":"AM Secora","year":"2020","unstructured":"Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, et al. Hyperkalemia and acute kidney injury with spironolactone use among patients with heart failure. Mayo Clin Proc. 2020;95(11):2408\u201319. https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.035.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2198_CR120","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/pds.3748","volume":"24","author":"S Abbas","year":"2015","unstructured":"Abbas S, Ihle P, Harder S, Schubert I. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24(4):406\u201313. https:\/\/doi.org\/10.1002\/pds.3748.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2198_CR121","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ejhf.226","volume":"17","author":"A Michel","year":"2015","unstructured":"Michel A, Martin-Perez M, Ruigomez A, Garcia Rodriguez LA. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail. 2015;17(2):205\u201313. https:\/\/doi.org\/10.1002\/ejhf.226.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2198_CR122","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijcard.2014.02.034","volume":"173","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol. 2014;173(3):380\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2014.02.034.","journal-title":"Int J Cardiol"},{"issue":"20","key":"2198_CR123","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1001\/jama.2012.14795","volume":"308","author":"A Hernandez","year":"2012","unstructured":"Hernandez A, Mi X, Hammill B, Hammill SC, Heidenreich P, Masoudi F, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097\u2013107. https:\/\/doi.org\/10.1001\/jama.2012.14795.","journal-title":"JAMA"},{"issue":"5","key":"2198_CR124","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","volume":"24","author":"AS Desai","year":"2018","unstructured":"Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018;24(5):313\u201320. https:\/\/doi.org\/10.1016\/j.cardfail.2018.03.002.","journal-title":"J Card Fail"},{"issue":"8","key":"2198_CR125","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ejhf.1860","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail. 2020;22(8):1462\u201371. https:\/\/doi.org\/10.1002\/ejhf.1860.","journal-title":"Eur J Heart Fail"},{"key":"2198_CR126","doi-asserted-by":"crossref","unstructured":"Wang W, Gu L, Zang X, Liu N, Pan Y, Jiang C, et al. Sodium zirconium cyclosilicate (SZC) to enable renin angiotensin aldosterone system inhibitor (RAASi) use for diabetic kidney disease: the CRYSTAL study. Late-Breaking Science Posters. 2024.","DOI":"10.1681\/ASN.20248hk24vms"},{"issue":"41","key":"2198_CR127","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401.","journal-title":"Eur Heart J"},{"issue":"10","key":"2198_CR128","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050\u20136. https:\/\/doi.org\/10.1002\/ejhf.300.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2198_CR129","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057\u201365. https:\/\/doi.org\/10.1002\/ejhf.402.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2198_CR130","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502.","journal-title":"Eur Heart J"},{"issue":"2","key":"2198_CR131","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"JC Tardif","year":"2023","unstructured":"Tardif JC, Rouleau J, Chertow GM, Al-Shurbaji A, Lisovskaja V, Gustavson S, et al. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail. 2023;10(2):1066\u201376. https:\/\/doi.org\/10.1002\/ehf2.14268.","journal-title":"ESC Heart Fail."},{"key":"2198_CR132","unstructured":"Kosiborod M, Cherney D, Desai A, Testani J, Verma S, Dahl M, et al. Sodium zirconium cyclosilicate and MRA optimization in heart failure with reduced ejection fraction and hyperkalemia: main results from REALIZE-K randomized controlled trial. Saint Luke\u2019s Mid America Heartinstitute. 2024."},{"issue":"4","key":"2198_CR133","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdi.12629","volume":"8","author":"LJ Sun","year":"2017","unstructured":"Sun LJ, Sun YN, Shan JP, Jiang GR. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diabetes Investig. 2017;8(4):609\u201318. https:\/\/doi.org\/10.1111\/jdi.12629.","journal-title":"J Diabetes Investig."},{"issue":"8","key":"2198_CR134","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/CJN.0000000000000205","volume":"18","author":"X Luo","year":"2023","unstructured":"Luo X, Xu J, Zhou S, Xue C, Chen Z, Mao Z. Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis. Clin J Am Soc Nephrol. 2023;18(8):1019\u201330. https:\/\/doi.org\/10.2215\/CJN.0000000000000205.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"2198_CR135","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.05.079","volume":"84","author":"B Pitt","year":"2024","unstructured":"Pitt B, Anker SD, Lund LH, Coats AJS, Filippatos G, Rossignol P, et al. Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist therapies in patients with heart failure and hyperkalemia. J Am Coll Cardiol. 2024;84(14):1295\u2013308. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.079.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2198_CR136","doi-asserted-by":"publisher","first-page":"sfae083","DOI":"10.1093\/ckj\/sfae083","volume":"17","author":"A Rastogi","year":"2024","unstructured":"Rastogi A, Pollack CV Jr, Sanchez Lazaro IJ, Lesen E, Arnold M, Franzen S, et al. Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study. Clin Kidney J. 2024;17(5):sfae083. https:\/\/doi.org\/10.1093\/ckj\/sfae083.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2198_CR137","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","volume":"3","author":"CB Bowling","year":"2010","unstructured":"Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3(2):253\u201360. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.899526.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2198_CR138","doi-asserted-by":"publisher","first-page":"CD013165","DOI":"10.1002\/14651858.CD013165.pub2","volume":"6","author":"P Natale","year":"2020","unstructured":"Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):CD013165. https:\/\/doi.org\/10.1002\/14651858.CD013165.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4S","key":"2198_CR139","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"6","key":"2198_CR140","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3969\/j.issn.1000-3614.2024.06.002","volume":"39","author":"Cardiovascular Medicine Branch of Chinese Physicians Association, Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics","year":"2024","unstructured":"Cardiovascular Medicine Branch of Chinese Physicians Association, Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics. Chinese expert consensus on prevention and treatment of hyperkalemia related to heart failure medication therapy. Chin Circ J. 2024;39(6):537\u201346. https:\/\/doi.org\/10.3969\/j.issn.1000-3614.2024.06.002.","journal-title":"Chin Circ J"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02198-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02198-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:04:08Z","timestamp":1754391848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02198-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":140,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2198"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02198-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"11 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by grants from the National Natural Science Foundation of China (Nos. 82170737, 82200820, and 82370707), NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University), Guangzhou Science and Technology Project (No. 2025A04J5292, 202206080010), Guangdong Provincial Key Laboratory of Nephrology, Guangdong International Science and Technology Cooperation Institute of Immune Kidney Disease and Precision Medicine, Guangdong Basic and Applied Basic Research Foundation (No. 2023B0303000013), and 2024 Guangzhou Science and Technology Fund for Agriculture and Social Development Special Topic (No. 2024B03J1337). This work also received funding from AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors (NH, YX, CL, YL, YF, ZL, DZ, HM, WC) declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"NH, YX, CL, DZ, HM, and WC conceived and designed the study. NH, YX, CL, YL, YF, ZL, and DZ screened and selected the articles. NH, YX, CL, YF, and ZL extracted the data. NH, YX, CL, YF, and ZL assessed the risk of bias, NH, CL, YF, and ZL analyzed the data, HM, and WC supervised the data analyses, NH, and CL rated the certainty of evidence, NH, YX, and WC interpreted the data, NH, CL, YF, and ZL drafted the manuscript. All authors had full access to all the data in the study, had reviewed and approved the final version of the manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}